¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"pain receptor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • delayed pain
    Áö¿¬ÅëÁõ
  • dental pain
    Ä¡Åë
  • deafferentation pain
    µé±æÂ÷´ÜÅëÁõ, ±¸½É·ÎÂ÷´ÜÅëÁõ
  • dragging pain
    °ßÀÎÅë
  • ear pain
    ±ÍÅëÁõ, ±Í¾ÎÀÌ
  • excruciating pain
    °Ý½ÉÅë
  • exertional chest pain
    ¿îµ¿¼º°¡½¿ÅëÁõ, ¿îµ¿¼ºÈäÅë
  • expulsive pain
    ¹èÃâÅë, ¸¸ÃâÁøÅë
  • epigastric pain
    ¸íÄ¡ÅëÁõ
  • false pain
    °ÅÁþºÐ¸¸Åë, °¡ºÐ¸¸Åë
  • fulgurant pain
    Àü°ÝÅëÁõ
  • girdle pain
    ¶ìÅëÁõ, ´ë»óÅëÁõ
  • gnawing pain
    ÂÉ´ÂÅëÁõ, ¼±Åë
  • griping pain
    ±ÞÅëÁõ, Á¶ÀÓÅë
  • growing pain
    ¼ºÀåÅëÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • dragging pain
    °ßÀÎÅë
  • dull pain
    µÐÅë
  • myofascial pain dysfunction
    ±ÙÀ°±Ù¸·ÅëÁõ±â´ÉÀå¾Ö
  • postejaculatory pain disorder
    »çÁ¤ÈÄÅëÁõÀå¾Ö, »çÁ¤ÈÄÅëÁõº´
  • psychogenic pain disorder
    Á¤½Å¼ºÅëÁõÀå¾Ö, Á¤½Å¼ºÅëÁõº´, Á¤½ÅÅ¿ÅëÁõÀå¾Ö
  • somatoform pain disorder
    ½ÅüÇüÅëÁõÀå¾Ö, ½ÅüÇüÅëÁõº´
  • ear pain
    ±Í¾ÎÀÌ, ±ÍÅëÁõ
  • excruciating pain
    °ÝÅë
  • expulsive pain
    ¹èÃâÅë, ¸¸ÃâÁøÅë
  • facet joint pain syndrome
    ôÃßÈİüÀýÅëÁõÈıº
  • false pain
    °¡ÁøÅë, °¡ºÐ¸¸Åë, °ÅÁþºÐ¸¸Åë
  • fulgurant pain
    (¢¡lightning pain) Àü°ÝÅëÁõ
  • girdle pain
    ´ë»óÅëÁõ, ¶ìÅëÁõ
  • gnawing pain
    ¼±Åë, ÂÉÀ½ÅëÁõ
  • griping pain
    ½ÉÇѺ¹Åë, ¿òÅ´ÅëÁõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • postprandial pain
    ½ÄÈļº ÅëÁõ.
  • postprandial pain
    ½ÄÈļº ÅëÁõ(ãÝý­àõ ÷Ôñø)
  • posttraumatic pain
    ¿Ü»óÈÄ(µ¿)Åë(Áõ).
  • posttraumatic pain
    ¿Ü»óÈÄÅëÁõ(µ¿Åë)
  • precordial pain =precordialgia
    ¸íÄ¡µ¿Åë.
  • precordial pain =precordialgia
    ¸íÄ¡µ¿Åë(¡­ÔÙ÷Ô)
  • pressure pain
    ¾ÐÅë(äâ÷Ô).
  • pressure pain
    ¾ÐÅë(äâ÷Ô)
  • prick pain
    ÀÚÅë(ô§÷Ô).
  • prick pain
    ÀÚÅë(ô§÷Ô)
  • primary (pain) neuron
    ÀÏÂ÷(Åë)´º¿ì·Ð.
  • primary (pain) neuron
    ÀÏÂ÷(Åë)´º¿ì·Ð.
  • primary pain
    ¿ø¹ß¼º ÅëÁõ.
  • psychogenic pain
    ½ÉÀμº µ¿Åë
  • psychogenic pain disorder
    ½ÉÀμº µ¿ÅëÀå¾Ö(º´).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • receptor hypothesis
    ¼ö¿ëü°¡¼³
  • receptor imaging
    ¼ö¿ëü¿µ»ó(È­)
  • receptor organ
    ¼ö¿ë±â°ü(áôé»Ðïί).
  • receptor potential
    ¼ö¿ë±âÀüÀ§.
  • receptor sensitivity
    ¼ö¿ëü °¨¼ö¼º
  • receptor site
    ¼ö¿ëüºÎÀ§.
  • receptor stimulants
    ¼ö¿ëüÀÚ±ØÁ¦.
  • receptor supersensitivity
    ¼ö¿ëü Ãʰ¨¼ö¼º(áôéÄô÷ õ±Êïáôàõ)
  • receptor, T cell
    T¼¼Æ÷(Ç׿ø)¼ö¿ëü
  • receptor-ligand interaction
    ¼ö¿ëü-¹èÀ§ÀÚ »óÈ£ÀÛ¿ë
  • retinoic acid receptor
    ·¹Æ¼³ëÀλê¼ö¿ëü
  • retinoid acid receptor alpha=RARA
    ¾ËÆÄ·¹Æ¼³ëÀÍ»ê¼ö¿ëü
  • secondary receptor
    ÀÌÂ÷¼º ¼ö¿ë±â(¡­áôé»Ðï).
  • sensory receptor
    °¨°¢¼ö¿ëü.
  • sigma receptor
    ½Ã±×¸¶¼ö¿ëü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
C&P compensation and pension; complete and pain free [joint movement]; cystoscopy and pyelography
CPC central posterior curve; cerebellar Purkinje cell; cerebral palsy clinic; cerebral performance categ...
CPOTHA chest pain onset to hospital arrival
CPP cancer proneness phenotype; canine pancreatic polypeptide; cerebral perfusion pressure; chest pain p...
CPSP central poststroke pain
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
SMP Sympathetically Maintained Pain
TMPDS Temporo-Mandibular Pain and Dysfunction Syndrome
TOTPAR Total Pain Relief
VAPS Visual Analogue Pain Score
VAS Visual analog pain scale
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • face pain
    ¾È¸éÅë
  • facial pain
    ¾È¸é ÅëÁõ, ¾È¸é µ¿Åë, ¾È¸éÅë
    Ä¡°ú Àǻ翡°Ô ¾È¸é µ¿ÅëÀÇ Áø´ÜÀº ¸Å¿ì ¾î·Á¿î ÀÏÀÌ´Ù. ¾È¸éºÎ µ¿ÅëÀÇ ¼º°øÀû Áø´ÜÀº Á¤È®Çϰí ÀÚ¼¼ÇÑ µ¿ÅëÀÇ º´·Â°ú ¾È¸é°ú ¿¬°üºÎÀÇ ÀÚ¼¼ÇÑ ÀÓ»óÀû °Ë»ç ¹× ¾È¸é µ¿ÅëÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â Á¶°Ç¿¡ ´ëÇÑ ÇØ¹ÚÇÑ Áö½Ä¿¡ ´Þ·Á ÀÖ´Ù. ±¸°­°ú ¾È¸éÀÇ µ¿ÅëÀº Ä¡¼ºÀÏ ¼öµµ ÀÖ°í ¶Ç´Â ºñÄ¡¼ºÀÏ ¼öµµ ÀÖ´Ù. ºÒÇÊ¿äÇÑ ¹ßÄ¡¸¦ ÇÏÁö ¾Ê±â À§Çؼ­ Á¤È®ÇÑ Áø´ÜÀ» ÇØ¾ß ÇÑ´Ù.
  • facial pain of unknown origin
    ¿øÀÎ ºÒ¸íÀÇ ¾È¸é ÅëÁõ, Àڹ߼º ¾È¸é ÅëÁõ
  • false pain
    °¡¼º µ¿Åë
    ºÐ¸¸ ÁøÅë°ú ºñ½ÁÇϳª È¿°ú°¡ ¾ø´Â ÁøÅëÀ¸·Î Àڱà °æ°ü È®ÀåÀÌ ÀϾÁö ¾Ê´Â´Ù.
  • flank pain
    Ãøº¹ºÎ ÅëÁõ, Ãøº¹Åë
  • headache pain
    µÎÅë
  • heat pain
    ¿­Åë
    °¡¿­À̳ª ³Ã°¢¿¡ ´ëÇØ ÇǺΰ¡ ÀÏÁ¤ ¿ªÄ¡ ÀÌ»óÀÎ °æ¿ì Åë°¢À¸·Î ÀÎÁöÇØ ÅëÁõÀ» ´À³¢´Â °Í.
  • high pain threshold
    °í µ¿Åë ¿ªÄ¡
    ÅëÁõÀ» À¯¹ßÇØ ¹ÝÀÀÀ» ÀÏÀ¸Å°°Ô ÇÏ´Â ÃÖ¼ÒÇÑÀÇ ÀÚ±ØÀÇ °­µµ°¡ ³ôÀº °Í.
  • history of pain
    µ¿ÅëÀÇ º´·Â
  • homotopic pain
    µ¿¼ÒÅë
    â»óºÎ¿¡ ÀÏÄ¡ÇÏ¿© »ý±â´Â µ¿Åë.
  • hunger pain
    °øº¹Åë
    1. ´ÙÀ½ ½Ä»ç¸¦ Çϱâ Àü °øº¹°¨ÀÌ ³¯ ¶§ ÀϾ´Â µ¿ÅëÀ¸·Î À§ ÁúȯÀÇ ÇÑ Áõ»óÀÌ´Ù. 2. À½½Ä¹°À» ¼·ÃëÇÑ ¼ö ½Ã°£ ÈÄ °øº¹À» ´À³¥ ¹«·Æ¿¡ »óº¹ºÎ¿¡¼­ ÀÚ°¢µÇ´Â ÅëÁõ. ±â¾ÆÅëÀ̶ó°íµµ ÇÑ´Ù. À§ÀÇ ÃⱸÀÎ À¯¹®ºÎÀÇ ±Ë¾ç, ½ÊÀÌÁöÀå ±Ë¾ç µî¿¡¼­ ÈçÈ÷ º¼ ¼ö ÀÖ´Â Áõ¼¼ÀÌÁö¸¸, ÀÌ ¹Û¿¡ ´Ü¼øÇÑ À§¿°, ´ã³¶¿° µî¿¡¼­µµ ±×·¯ÇÑ Áõ¼¼°¡ ÀÖ´Ù. À§ À¯¹®ºÎÀÇ °æ·Ã Áõ¼¼¶ó°í ÁüÀ۵Ǵ °ÍÀ¸·Î, º¹ºÎ ÀÚÀ²½Å°æÀÇ ±äÀå°ú °ü°è°¡ ±í´Ù. À½½Ä¹°À» ¼·ÃëÇϰųª ¾ËÄ®¸®Á¦¸¦ º¹¿ëÇÏ¸é µ¿ÅëÀÌ ¿ÏÈ­µÉ ¼ö ÀÖ´Ù.
  • ideogenous pain
    °ü³ä¼º µ¿Åë
    ±×¸©µÈ °ü³ä¿¡ ÀÇÇÏ¿© ÀϾ´Â µ¿ÅëÀ¸·Î Á¤½ÅÀûÀ¸·Î »ý±ä´Ù.
  • idiopathic pain
    Àڹ߼º ÅëÁõ, Ư¹ß¼º µ¿Åë
    ¿øÀÎÀ̳ª º´¼Ò¸¦ ¸ð¸£´Â ÅëÁõ¼º ÁúȯÀ̳ª Àå¾Ö.
  • impirative pain
    °­¹Ú µ¿Åë
    ½Å°æ ¼è¾à ȯÀÚ¿¡°Ô »ý±â´Â Áö¼ÓÀûÀÎ µ¿Åë °¨°¢.
  • initial pain
    Ãʱ⠵¿Åë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
receptor, chemokine A molecule that receives a chemokine and acts as a dock for a chemokine. Several chemokine receptors are essential co-receptors for HIV.
(12 Dec 1998)
receptor downregulation A phenomenon observed in many cells: following stimulation with a ligand the number of receptors for that ligand on the cell surface diminishes because internalisation exceeds replenishment. Often used very loosely, thus destroying the utility of the term.
(18 Nov 1997)
receptor mediated endocytosis Endocytosis of molecules by means of a specific receptor protein that normally resides in a coated pit, but may enter this structure after complex formation occurs. The structure then forms a coated vesicle that delivers its contents to the endosome whence it may enter the cytoplasm or the lysosomal compartment. Many bacterial toxins and viruses enter cells by this route.
(18 Nov 1997)
receptor potential The transmembrane potential difference of a sensory cell. Such cells are not generally excitable, but their response to stimulation is a gradual change in their resting potential.
(18 Nov 1997)
receptor protein An intracellular protein (or protein fraction) that has a high specific affinity for binding a known stimulus to cellular activity, such as a steroid hormone or adenosine 3',5'-cyclic phosphate.
(05 Mar 2000)
receptor protein-tyrosine kinase <enzyme> A catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of receptors. Many growth and differentiation factor receptors contain this domain. It is critical for the signal transduction pathways required for mitogenesis, transformation, and cell differentiation.
Registry number: EC 2.7.1.-
(12 Dec 1998)
receptor site Point of attachment of viruses, hormones, or other activators to cell membranes.
(05 Mar 2000)
receptor tyrosine kinase Class of membrane receptors that phosphorylate tyrosine residues. Many play significant roles in development or cell division.
Examples: insulin receptor family, c ros receptor, Drosophila sevenless, trk family.
(18 Nov 1997)
receptor, visual The layer of rods and cones, the visual cells, of the retina.
(12 Dec 1998)
Cek4 receptor protein-tyrosine kinase <enzyme> Isolated from mouse and chicken.
Registry number: EC 2.7.1.-
Synonym: cek4 protein, cek4 eph receptor, eph receptor cek4
(26 Jun 1999)
visual receptor cells The rod and cone cell's of the retina.
(05 Mar 2000)
glutamate receptor <physiology> See amino acid receptor superfamily. Glutamate receptors are implicated in many important brain functions including long-term potentiation (LTP).
at least 4 major glutamate gated ion channel subtypes are presently distinguished on pharmacological grounds, named after their most selective agonists: N methyl D aspartate (NMDA implicated in memory and learning, neuronal cell death, ischaemia and epilepsy), kainic acid (KA), quisqualate/AMPA and L 2 amino 4 phosphobutyrate (APB). A fifth subtype (APCD) trans 1 amino cyclopentane 1,3 dicarboxylate is a G-protein coupled receptor.
(18 Nov 1997)
glycine receptor <physiology> Chloride channel forming receptor. One of a family of neurotransmitter receptors with fast intrinsic ion channels.
See: amino acid receptors.
(18 Nov 1997)
peptide receptor Specific receptor for peptide neurotransmitters.
(18 Nov 1997)
G-protein coupled receptor <cell biology> Cell surface receptors that are coupled to G-proteins (GTP-binding protein).
G-protein coupled receptors are thought to have seven membrane spanning domains and have been divided into 2 subclasses: those in which the binding site is in the extracellular domain for example receptors for glycoprotein hormones, such as thyroid stimulating hormone (TSH) and follicle-stimulating hormone (FSH) and those in which the ligand binding site is likely to be in the plane of the 7 transmembrane domains for example rhodopsin and receptors for small neurotransmitters and hormones for example muscarinic acetylcholine receptor.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á